Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Wolfram and Classiq Integrate Advanced Quantum Software Tools into Mathematica

Classiq Technologies

In a landmark collaboration, Classiq, a leader in quantum computing software, and Wolfram Research, the leading computational software provider, announce a software partnership. This collaboration integrates Classiq’s cutting-edge engine within Wolfram Mathematica, offering a unified solution for the development of quantum and classical algorithms. This integration is targeted at enabling users to leverage the robust capabilities of Wolfram Mathematica for algorithm development and utilize Classiq’s Quantum Model (QMOD) language for quantum algorithm development—all within a single, cohesive environment. This blend of technologies empowers users to define, visualize and optimize quantum algorithms with unprecedented ease and efficiency. Key features of this collaboration are the facilitation of Classiq’s quantum algorithm compilation tailored to specific quantum hardware and ability to intricately develop quantum circuits from a high-level overview down to detailed gate operations. The integration further allows for the execution of these quantum circuits across a diverse array of backends and simulators, directly within the Mathematica notebook. This integration supports researchers by enhancing analytical capabilities, enabling continuous exploration and data assessment. As an example of the potential of this collaboration, the Quantum Differential Equations solver exemplifies how users will be able to tackle complex challenges by defining and executing quantum algorithms like the Harrow–Hassidim–Lloyd (HHL) algorithm and Quantum Singular Value Transformation (QSVT) for matrix inversion, directly from the Mathematica interface. This application highlights the power of combining classical computational methods with quantum processing to solve complex computational problems more efficiently. “The partnership between Classiq Technologies and Wolfram Research reflects a shared commitment to advancing computational excellence,” said Nir Minerbi, CEO of Classiq. “This collaboration not only enhances the toolset available for researchers and developers, we hope to see it pave the way for groundbreaking applications across various scientific and engineering disciplines.” "In the pursuit of applying quantum technologies to address real-world challenges, robust collaboration among industry leaders is paramount. We are delighted to unveil our strategic partnership with Classiq," remarked Mads Bahrami, quantum projects manager at Wolfram. "This partnership underscores the dedication of both entities towards crafting toolsets that empower governments, industries, and academia to tackle complex problems through quantum-classical algorithms." The companies invite those seeking to combine the best of quantum and classical computation to reach out and explore the possibilities this computation integration brings. About Wolfram Founded by Stephen Wolfram in 1987, Wolfram Research is one of the world's most respected computer, web and cloud software companies - as well as a powerhouse of scientific and technical innovation. As a pioneer in computation and computational knowledge, Wolfram has pursued a long-term vision to develop the science, technology and tools to make computation an ever-more-potent force in today's and tomorrow's world. As the creators of Mathematica, Wolfram|Alpha, the Wolfram Language, and Wolfram Quantum Framework, Wolfram is the leader in developing technology and tools that inject sophisticated computation and knowledge into everything. Wolfram's strategy as an organization is to maintain a portfolio of development, from continually strengthening core algorithms and the Wolfram Knowledgebase, to supporting the latest computing and deployment architectures, to developing major new concepts and capabilities - and consistently delivering the results in the form of products, services and experimental initiatives that make breakthrough technology accessible to the broadest possible spectrum of people and organizations. Learn more at: https://wolfr.am/QuantumConsulting https://www.wolfram.com/quantum-computation-framework/ Follow Wolfram on LinkedIn, X, and YouTube. Contact Wolfram quantum team: quantum@wolfram.com Contact Wolfram PR team: outreach@wolfram.com About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq's core technology - algorithmic quantum circuit compilation - is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq's world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more. Contact Details Rainier Communications Michelle McMahon +1 781-718-3248 classiqPR@rainierco.com Company Website http://www.classiq.io/

April 23, 2024 08:00 AM Eastern Daylight Time

Capturing Consumer Spending on Health Care with XLV

Select Sector SPDR

With consumer spending on health care continuing to increase, the Health Care Select Sector SPDR Fund ( XLV ) provides an opportunity for investors to leverage this trend. XLV tracks health care stocks within the S&P 500 Index, offering broad exposure to core companies in the U.S. healthcare sector. The fund's top holdings* are comprised of market leaders across several sub-sectors of healthcare including companies such as Eli LIlly & Co (11.34%), Unitedhealth Group (8.36%), Johnson & Johnson (6.96%), Merck & Co (6.11%), AbbVie Inc. (5.87%), Thermo Fisher Scientific (4.10%), Abbott Laboratories (3.61%), Danaher Corp (3.00%), Pfizer (2.86%), and Amgen (2.78%). Growth Drivers in the Healthcare Sector As the health care sector continues to grow, these companies are well-positioned to benefit from increased consumer spending. The growth history in this sector has been driven by several factors, including a rise in chronic diseases, an aging population, and advancing medical technology. Total spending on health care rose from 16% of GDP in 2007 to an estimated 18% in 2023. Simultaneously, the total GDP has risen nearly 70% in that time, from 14.47 trillion in 2007 to 25.5 trillion in 2022. Investing in XLV offers a diversified way to capture steady consumer spending on health care. By investing in the health care market in a broad way, the ups and downs of a particular big name in the sector are mitigated by the exposure to other healthcare companies. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 3/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007449 EXP 5/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

April 22, 2024 05:00 AM Eastern Daylight Time

Elsevier Appoints Dr Kieran West MBE as Executive Vice President of Strategy

Elsevier

Elsevier, a global leader in scientific information and analytics, announced today the appointment of Dr Kieran West MBE as Executive Vice President of Strategy, effective immediately. As an established senior executive with a track record of driving transformation and growth, Kieran joins Elsevier with extensive experience in healthcare, retail, consumer goods, and pharmaceuticals across international markets. Most recently, he served as Strategy Director at Bupa Global and UK, a leading healthcare provider and insurer, where he was instrumental in shaping the company's strategic direction. Prior to his time at Bupa, he served as an Associate Partner at McKinsey, where he advised both domestic and global companies on achieving commercial success. He previously taught mathematics at King’s College School, UK. His academic achievements include a PhD in History from the University of Cambridge, an MA in War Studies from King’s College London, and a PGCE degree in Mathematics. Kieran is also a world champion rower and Olympic gold-medallist, having won in the Men’s Eights in the 2000 Sydney Olympics. Kumsal Bayazit, CEO of Elsevier, said: “I am thrilled to welcome Kieran to Elsevier and look forward to the contribution that he will make with his strong strategic and operational experience, and his understanding of the healthcare, life sciences and academic communities. He is also passionate about developing individuals and delivering as a team, which is very much aligned with our values as an organization.” Kieran joins Elsevier’s Executive Leadership Team and will work across all areas of the company to develop and drive global strategic plans, including business development initiatives. He will be based in London. About Elsevier As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies. We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com. Contact Details Dan DiPietro-James +1 323-252-0645 Dan.james@elsevier.com

April 22, 2024 04:00 AM Eastern Daylight Time

UNOS unveils new artwork honoring organ donors and recipients

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) installed a mural by acclaimed artist Hamilton Glass to recognize the far-reaching impact of organ donation and to pay tribute to organ donors. The artwork is a Glass original, designed specifically for UNOS, and lives above the main entrance of UNOS’ headquarters in Richmond, Va. The mural portrays the interconnectedness of the organ donation and transplant community, with hands symbolizing the gesture of giving and receiving the gift of life. The blue ripples illustrate the ripple effect of donation on families and communities. “The artwork serves as a poignant reminder that every donation is a gift that touches us all, creating a network of support that UNOS tirelessly collaborates with daily to save lives,” said Glass. UNOS invited Richmond-based architect and artist Glass and his wife and business partner Taekia to design and create a piece of art that visually connects to and builds on the meaning of the National Donor Memorial. The memorial honors organ, eye and tissue donors and is open 24/7 to allow visitors to reflect on the journey of donation and transplant. “The lifesaving and lifechanging impact an organ donor has on both a recipient and their loved ones is incredibly profound, which is why we wanted to work with Hamilton Glass to create a piece of art that honors the selfless gifts organ donors provide,” said Maureen McBride, Ph.D., CEO of UNOS. “We want people to visit this mural and take in and learn how significant and impactful organ donation is.” Glass uses art to engage the public through big, bold designs and messages of hope, and has more than 300 murals on display throughout Richmond. The mural is approximately 16 feet tall and 40 feet wide and is comprised of 18 PVC panels. It is located on the exterior of UNOS’ building on North 4th Street in Richmond, Va. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

April 19, 2024 03:54 PM Eastern Daylight Time

Image

CURE ALZHEIMER’S FUND REACHES $200 MILLION IN RESEARCH GRANTS

Alzheimer’s Disease Research Foundation

April 18, 2024 — Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, announced today that it has reached an important milestone—awarding more than $200 million in research grants to leading scientists throughout the world investigating the disease. Since its establishment in 2004, Cure Alzheimer’s Fund (CureAlz) has supported more than 840 innovative grants led by more than 300 scientists resulting in 1,182 published peer-reviewed papers in prominent scientific journals. Many of these projects have yielded significant breakthroughs, resulting in findings contributing to new and critical avenues for development of novel treatments. “CureAlz was founded with one mission: to fund research that will accelerate prevention, treatment and a cure for this disease,” said Henry McCance, Chair of Cure Alzheimer’s Fund. “Since the beginning, our approach has attracted others to join us in this fight, all who have been vital to what we have achieved. It has been an honor to deploy more than $200 million dollars in funding that is enabling and accelerating extraordinary research pursued by brilliant and determined scientists around the world.” Funded projects have included: · The Alzheimer’s Genome Project, the first large-scale, family-based study of the human genome specific to Alzheimer’s disease. · Projects that explore how the body’s complex immune responses may contribute to Alzheimer’s disease. · A consortium of experts to expand our understanding of the role the APOE gene may have in Alzheimer’s disease. “For 19 years, our Founders and Board of Directors have been steadfast in their commitment to our mission to end the terrible burden of Alzheimer’s. The field’s top scientists contribute their expertise and guidance to CureAlz, meaning science and data are always our lodestars to a cure,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Our leadership’s vision, drive and generosity are matched by that of our dedicated donor and researcher communities. We celebrate this milestone as the shared achievement it is, and at the same time rededicate ourselves to accelerating an end to Alzheimer’s.” Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided more than 840 grants to more than 300 of the world’s leading researchers and contributed more than $200 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. Our Board of Directors, Trustees, and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. To learn about the impact of Alzheimer’s on women and women working towards a cure, WomenandAlzheimers.org. Contact Details Barbara Chambers +1 978-417-9890 BChambers@CureAlz.org Company Website https://curealz.org

April 18, 2024 08:00 AM Eastern Daylight Time

Isospec Analytics raises $1.9m as it introduces breakthrough technology to rapidly identify unknown molecules at scale

Isospec Analytics

When developing new drugs, nutitional products, or pesticides, it’s critical that unknown molecules are identified correctly. But accurate identification is a lengthy process and all too often unsuccessful, leading to failed regulatory processes, or worse, consumer health being put in danger. Today, Isospec Analytics has raised $1.9M to commercialize new technologies for molecular analysis that rapidly identify unknown molecules in minutes, helping pharmaceuticals, nutrition and agritech companies develop safer products and enabling researchers to discover new biomarkers. Isospec’s $1.9M pre-seed round is led by Founderful (formerly Wingman Ventures), with additional participation from specialized investors Tiny.vc, another.vc and Venture Kick. Isospec was founded in 2022 by Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, who partnered together to explore how they could redefine the process of molecular analysis to access new biological information and enable breakthroughs in diagnostics, therapeutics, and nutrition. Based on over 20 years of research, the founders combined technologies from multiple disciplines – analytical chemistry, photonics, and cryogenic materials initially designed for space applications – to build a tool that can generate a new data dimension about molecular structures. This allows for the identification of molecules which were, until now, unknown. Today, identifying an unknown molecule is primarily based on mass analysis, which does not provide sufficient information. Identifying a by-product or an impurity requires the combination of high sensitivity to detect trace amounts in a sample, coupled with the ability to generate data that can definitively identify the structure of a molecule. Existing tools lack either one or both of these capabilities. “Unfortunately, mass alone does not uniquely determine the structure of a molecule. Several different molecules can have exactly the same mass, called isomers, but totally different properties. For example, one isomer might be toxic, while another may be a life-saving therapeutic,” said Thomas Rizzo, Professor of Chemistry at EPFL. Definitive molecular identification currently requires the combination of several techniques and a lengthy process including purification and multiple syntheses. Companies developing new products are thus faced with a dilemma: either spend months identifying unknowns and delay their go-to-market, or move forward based on guesses and risk failing regulatory requirements and endanger consumer health. In comparison, Isospec’s technology generates unique, information-rich metrics that allow for the rapid identification of unknown molecules in minutes instead of months, bringing unprecedented scalability to molecular identification. “By adding infrared analysis directly inside a mass spectrometer, we have a valuable new dimension by which to identify molecules,” adds Professor Thomas Rizzo. Originating from the Laboratory of Molecular Physical Chemistry (LCPM) at EPFL, Isospec’s breakthrough technology is already being used in the analysis of sugars and metabolites within the food and agritech industry to carry out quality control and support product R&D. However, the team believes the real potential of their technology is in the discovery of new biomarkers for therapeutics development and diagnostics. “In a human blood sample, there are 15,000 small biological molecules that can give precise information about a person’s health at any given time. However, less than 5% of these molecules can be identified. The ability to rapidly identify new molecules means we can now leverage the 95% unknown molecular space to develop treatments to the deadliest diseases,” said co-founder and CEO Dr. Ahmed Ben Faleh. These combined use cases were compelling for Isospec’s investors. “Isospec’s value proposition, which offers early access to its cutting-edge research in biomolecular analysis as a service, convinced us of the potential of the technology and the team,” explains Alex Stöckl, partner at Founderful and board member of Isospec. “Isospec is one of the first 8 companies in which we have invested with our second fund, which aims to reach $120M.” The team is currently working on the scalability of their platform, introducing automation at every step and implementing machine learning tools for data analysis and insight generation. “This round allows us to build a software team composed of experts in data engineering,” said Dr Ahmed Ben Faleh. Against the highly competitive backdrop of the sugar and metabolite analytical markets, Isospec is setting its sights on becoming the leading provider of molecular analysis solutions and biomarker discovery technology. About Isospec Isospec Analytics is an EPFL spin-off based in Lausanne – Switzerland, whose mission is to implement technology to discover new disease biomarkers, accelerate the development of therapeutics and transform the future of clinical nutrition. For more information please visit IsoSpec Analytics About Founderful Founderful is Switzerland’s leading pre-seed fund. We give every founder our deepest understanding and highest levels of support, and together, we’re building the future of the Swiss startup ecosystem. Contact Details isospec Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.isospecanalytics.com/

April 16, 2024 08:00 AM Eastern Daylight Time

Image

Comtex Launches Omnia: A Cutting-Edge News API Platform leveraging NLP and AI

Comtex

Comtex News Network, Inc (Comtex), a leading provider of news aggregation and distribution services to top firms in financial services, news publishing, syndication, and analytics, proudly announces the launch of its innovative API platform, Omnia. Omnia is a state-of-the-art API platform designed to revolutionize the way businesses access and utilize news content. Omnia empowers users with instant access to real-time streaming news, AI-generated article summaries, enhanced tagging and categorization based on NLP, advanced filtering, and access to an extensive catalog of curated news sources. Key Features of Omnia Include: Real-time Streaming News: Omnia provides real-time streaming news via websockets push and REST API for seamless integration into existing systems. Enhanced Tagging and Categorization: Leveraging AI and proprietary NLP-based algorithms, Omnia offers enhanced tagging and categorization of content, including press releases, earnings releases, product categories, and more. AI-Generated Article Summaries: Omnia utilizes AI to generate concise and searchable article summaries, enabling users to quickly grasp an article before reading it. Advanced Filtering: Omnia's advanced filtering capabilities allow users to customize their news feeds based on specific criteria, ensuring they receive only the most relevant content. Access to an extensive collection of curated, high-quality sources used by top companies in financial services, analytics, research and a broad range of industries. Omnia is designed for rapid integration and serves a variety of use cases, including training of LLMs, financial platforms, asset management, trading, academic research, legal research, market research, and much more. Commenting on the launch, Comtex CEO Kan Devnani said, "We are pleased to bring a flexible, state-of-the-art news platform with access to curated, premium news sources to market. Omnia is an extendable platform, combining AI with our rich experience applying NLP to news content. This will allow clients to derive more intelligence and insights from the news content we offer and help clients curate and identify the content most relevant to them. Comtex will use Omnia to deliver evolving analytics and insight to its users." Access to Omnia can be trialed by visiting https://www.comtex.com/api. Comtex encourages users to explore its features and capabilities. To learn more about Omnia and request a demo, please contact sales@comtex.com or visit https://www.comtex.com/api. About Comtex News Network, Inc (Comtex): Comtex News Network Inc (Comtex) is a leading provider of news aggregation services to top firms in financial services, news publishing, syndication, and analytics. With a wealth of experience and expertise, Comtex delivers comprehensive news solutions that empower businesses to make informed decisions and stay ahead of the competition. Comtex also offers syndication services to content providers and platforms to generate traffic to online content. Contact Details Comtex News Network Media Relations sales@comtex.com

April 12, 2024 02:01 PM Eastern Daylight Time

Select Sector SPDR ETFs: A Strategic Approach to Precision Investing and Customized Portfolios

Select Sector SPDR

In the dynamic world of investing, Exchange-Traded Funds ( ETFs ) have proved to be a powerful tool for investors seeking diversification, flexibility, and potentially a more sector-driven approach. Select Sector SPDR ETFs offer a focused approach to sector investing, enabling investors to specifically target sectors within the broader market. This method of investment strategy is designed to arm investors with greater control and flexibility over their portfolios. Select Sector SPDR ETFs segment the S&P 500 into 11 investable sectors, covering all broad market segments. They provide access to various industries, allowing investors to craft a diversified portfolio that aligns with their unique investment goals. This approach presents an excellent opportunity for both individual and institutional investors to effectively navigate the financial markets. Each ETF comprises well-known, large-cap companies from the S&P 500, ensuring broad exposure and diversification. The transparent nature of ETFs allows for daily disclosure of portfolio holdings and weightings, providing investors with visibility into their investments. The full lineup of Select Sector SPDR ETFs includes: Communication Services Select Sector SPDR Fund (XLC) Consumer Discretionary Select Sector SPDR Fund (XLY) Consumer Staples Select Sector SPDR Fund (XLP) Energy Select Sector SPDR Fund (XLE) Financials Select Sector SPDR Fund (XLF) Health Care Select Sector SPDR Fund (XLV) Industrials Select Sector SPDR Fund (XLI) Materials Select Sector SPDR Fund (XLB) Real Estate Select Sector SPDR Fund (XLRE) Technology Select Sector SPDR Fund (XLK) Utilities Select Sector SPDR Fund (XLU) These ETFs provide flexible, transparent, and low-cost investment options to both retail and institutional investors. The flexibility offered by these ETFs empowers investors to make strategic adjustments in their portfolios as market conditions change. This flexibility, combined with the transparency of daily disclosure of portfolio holdings, allows investors to always be aware of where their money is invested. Select Sector SPDR ETFs offer a unique opportunity to invest in various sectors with precision and flexibility. They provide a simplified approach to sector investing, allowing investors to customize their portfolios to meet their specific investment objectives. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007439 EXP 5/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

April 12, 2024 05:00 AM Eastern Daylight Time

Autonomix Medical (NASDAQ: AMIX) Is Cracking the Code Of The Peripheral Nervous System With Its Breakthrough Technology To Treat Diseases

Autonomix Medical, Inc.

By Faith Ashmore, Benzinga The peripheral nervous system (PNS) is the network of nerves that extend from the brain and spinal cord to all parts of the body. Its main function is to facilitate communication between the central nervous system (CNS) and the rest of the body. The PNS is divided into two components: the somatic nervous system, which controls voluntary movements and senses, and the autonomic nervous system, which controls involuntary bodily functions like heart rate and digestion. Simply put, the PNS plays a crucial role in nearly every disease because it is responsible for transmitting signals and information throughout the body. Overactive nerves, disruption, or dysfunction in the PNS can lead to a variety of health issues, including conditions like pain, cardiovascular disease, such as hypertension, as well as gastrointestinal disorders. While many biotechnology companies are looking to treat symptoms for various conditions, Autonomix Medical Inc. (NASDAQ: AMIX) is targeting the root of the issue, which they associate with the PNS. The company’s first-in-class technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals and perform nerve ablations, killing the nerve. This technology has the ability to sense individual neural signals with up to 3,000 times greater sensitivity than currently available technologies. The company says this breakthrough technology opens new possibilities in electrophysiology and pain management. Autonomix Medical aims to provide a comprehensive solution that combines the detection and treatment of nerve-related disorders in a single procedure, streamlining the process and potentially improving patient outcomes. Unlike the conventional ablation approaches, Autonomix Medical reports that its technology works like a GPS, allowing doctors to identify, treat and verify the right nerves causing the issue. The company is initially evaluating pancreatic cancer pain to demonstrate the ability of its technology. With current treatment options, pancreatic cancer-related pain can be particularly challenging to manage because it is located near critical nerves and vessels, leading to severe and treatment resistant pain. Traditional pain treatments can often prove inadequate, leaving patients in need of more effective solutions; some patients turn to opioids for relief. If Autonomix Medical’s ongoing trial is successful, it could pave the way for the company to target larger disease markets and expand the total opportunity for their technology, which they estimate exceeds $100 billion. Additionally, Autonomix believes it has the potential to decrease nationwide reliance on opioids, which could be a win for patients and physicians alike. Featured photo by Stefano Bucciarelli on Unsplash Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

April 11, 2024 08:55 AM Eastern Daylight Time

Image

1 ... 6 7 8 9 10 ... 139